Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repligen Corp (NQ: RGEN )

149.99 +3.25 (+2.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corp

< Previous 1 2 3 4 5 6 Next >
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Repligen's Strong Q3 Recovery: CEO Says Pharma Orders Rebound, Analytics Business Grows
Repligen Corporation (NASDAQ: RGEN) reported third-quarter (Q3) revenues of $141.19 million, down 30% Y/Y, beating the  
Via Benzinga
Repligen Corp. (NASDAQ: RGEN) is a Leading Gainer in 10/31 Morning Trading
Via Investor Brand Network
A Preview Of Repligen's Earnings
Via Benzinga
7 Analysts Have This to Say About Repligen
Via Benzinga
What 6 Analyst Ratings Have To Say About Repligen
Via Benzinga
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Reviewing Mailbag Items and 5 Stocks Indistinguishable From Magic
September wasn't a good month for the stock market, but there's plenty for investors to talk about. 
Via The Motley Fool
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.  
Via Benzinga
Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Powell Industries, Inc. (NASDAQ: POWL) shares jumped... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Repligen
Via Benzinga
Earnings Scheduled For October 31, 2023
Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of... 
Via Benzinga
Top 5 Health Care Stocks That May Collapse In July
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Over $6M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Monday, there were a few notable insider trades. 
Via Benzinga
Looking Into Repligen's Return On Capital Employed
Via Benzinga
Why Repligen Stock Is Sinking Today
Investors appear to be anticipating an underwhelming first-quarter report from the bioprocessing company. 
Via The Motley Fool
Why Shares of Repligen Rose This Week
The company is coming off a solid third quarter and is getting noticed by analysts. 
Via The Motley Fool
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
Repligen Expects Slower Growth In APAC, Builds Portfolio On Heels Of FlexBiosys Deal
Repligen Corp (NASDAQ: RGEN) reported Q1 FY23 sales of $182.66 million, down 12% Y/Y as reported,  
Via Benzinga
Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2023
Via Benzinga
This Analyst Is Bullish on Repligen's FlexBiosys Acquisition for Fluid Management Portfolio
Repligen Inc (NASDAQ: RGEN) agreed to acquire FlexBiosys Inc to build its Fluid Management franchise and add a full range of single-use bioprocessing bags and assemblies.  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Via Benzinga
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover
Danaher is reportedly looking to add to its wheelhouse to compete with Thermo. 
Via Investor's Business Daily
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Repligen Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) posted Q3 earnings of $40.41 million, an increase from Q2 of 18.96%. Sales dropped to $200.74 million, a 3.32% decrease between quarters. 
Via Benzinga
Recap: Repligen Q3 Earnings
Repligen (NASDAQ:RGEN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Repligen beat estimated earnings by... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.